,GENE,MUTATION_REMARK,GENOMIC_MUTATION_ID,FUSION_ID,MUTATION_AA_SYNTAX,DISEASE,ACTIONABILITY_RANK,DEVELOPMENT_STATUS,DRUG_COMBINATION,TESTING_REQUIRED,TRIAL_STATUS,TRIAL_ID,TRIAL_NAME,COMPLETION_STATUS,TRIAL_PRIMARY_COMPLETION_DATE,PATIENT_PRESCREENING,RESULTS_AVAILABILITY,PROGRESSION_REMARK,SOURCE_TYPE,SOURCE,TREATMENT_HISTORY,PATIENT_AGE,PRIMARY_OUTCOME_MEASURE,NUMBER_OF_PATIENTS,TREATED_NUMBER,CONTROL_NUMBER,CONTROL_TREATMENT,ORR_TREAT,ORR_CON,ORR_CI,ORR_PVAL,DOR_TREAT,DOR_CON,DOR_CI,DOR_PVAL,PFS_TREAT,PFS_CON,PFS_HR,PFS_CI,PFS_PVAL,TTP_TREAT,TTP_CON,TTP_HR,TTP_CI,TTP_PVAL,DCR_TREAT,DCR_CON,DCR_PVAL,OS_TREAT,OS_CON,OS_HR,OS_CI,OS_PVAL,OBJ_RR_TREAT,CR_COUNT,PR_COUNT,SD_COUNT,RFS_TREAT,RFS_CON,RFS_HR,RFS_CI,RFS_PVAL,BLOOD_RESPONSE,RESPONSE_VALUE,TIMEPOINT,CLASSIFICATION_ID,LAST_UPDATED,COSMIC_PHENOTYPE_ID,SITE_PRIMARY_COSMIC,SITE_SUBTYPE1_COSMIC,SITE_SUBTYPE2_COSMIC,SITE_SUBTYPE3_COSMIC,HISTOLOGY_COSMIC,HIST_SUBTYPE1_COSMIC,HIST_SUBTYPE2_COSMIC,HIST_SUBTYPE3_COSMIC
0,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
1,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
2,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
3,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
4,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
5,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
6,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
7,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
8,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
9,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
10,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
11,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
12,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
13,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
14,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
15,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
16,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
17,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
18,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
19,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
20,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
21,AFP,AFP_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Best supportive care + Ramucirumab,Required,Completed,NCT02435433,REACH-2,PCD,2018Mar15,Expression confirmed,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,,,Overall survival,292.0,197.0,95.0,Best supportive care + Placebo,4.6,1.1,,,,,,,2.8,1.6,0.45,0.34-0.60,<0.0001,,,,,,,,,8.5,7.3,0.71,0.53-0.95,0.020,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
22,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
23,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
24,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
25,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
26,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
27,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
28,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
29,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
30,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
31,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
32,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
33,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
34,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
35,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
36,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
37,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
38,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
39,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
40,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
41,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
42,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
43,ALK,ALK_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Ascrinvacumab,,Terminated,NCT01911273,,PCD,2014Jul01,No,Yes,Development discontinued,3,NCT01911273,Previously-treated,,Overall survival,3.0,,,Best supportive care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
44,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
45,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
46,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
47,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
48,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
49,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
50,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
51,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
52,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
53,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
54,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
55,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
56,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
57,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
58,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
59,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
60,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
61,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
62,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
63,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
64,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
65,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,7,Phase 2,Temozolomide + Veliparib,,Terminated,NCT01205828,,PCD,2014Oct01,No,Yes,No benefit of treatment,4,NCT01205828,,,"Disease control rate, Clinical benefit rate",16.0,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
66,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
67,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
68,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
69,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
70,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
71,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
72,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
73,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
74,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
75,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
76,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
77,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
78,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
79,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
80,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
81,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
82,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
83,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
84,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
85,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
86,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
87,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Pembrolizumab,Not required,"Active, not recruiting",NCT02702414,KEYNOTE-224,PCD,2021Jan19,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s133lbl.pdf,,,Overall Response Rate,104.0,104.0,,,17,,11-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov30,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
88,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
89,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
90,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
91,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
92,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
93,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
94,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
95,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
96,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
97,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
98,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
99,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
100,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
101,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
102,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
103,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
104,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
105,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
106,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
107,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
108,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
109,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Approved FDA,Atezolizumab + Bevacizumab,Not required,"Active, not recruiting",NCT03434379,IMbrave150,PCD,2020Aug31,No,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf,Untreated,,"OS, PFS",501.0,336.0,165.0,Sorafenib,28,12,,<0.0001,,6.3,,,6.8,4.3,0.59,0.47-0.76,<0.0001,,,,,,,,,,13.2,0.85,0.42-0.79,0.0006,,,,,,,,,,,,,COSO29825606,2023Jan23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
110,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
111,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
112,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
113,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
114,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
115,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
116,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
117,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
118,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
119,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
120,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
121,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
122,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
123,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
124,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
125,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
126,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
127,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
128,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
129,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
130,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
131,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Durvalumab + Tremelimumab,,Recruiting,NCT04605731,,ECD,2023Dec31,No,No,,4,NCT04605731,,,Overall Response Rate,32.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug01,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
132,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
133,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
134,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
135,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
136,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
137,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
138,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
139,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
140,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
141,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
142,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
143,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
144,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
145,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
146,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
147,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
148,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
149,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
150,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
151,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
152,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
153,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Apatinib + Camrelizumab,,Recruiting,NCT04701060,,ECD,2022Feb04,No,No,,4,NCT04701060,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
154,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
155,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
156,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
157,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
158,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
159,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
160,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
161,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
162,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
163,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
164,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
165,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
166,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
167,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
168,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
169,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
170,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
171,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
172,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
173,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
174,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
175,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Bevacizumab + Toripalimab,,"Active, not recruiting",NCT04605796,,PCD,2020Dec22,No,Yes,SAE 27.8%,2,10.1200/JCO.2022.40.4_suppl.435,,,Overall Response Rate,52.0,52.0,,,37.2,,,,,,,,9.9,,,5.5-11.0,,,,,,,78.8,,,,,,,,,1.0,16.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
176,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
177,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
178,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
179,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
180,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
181,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
182,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
183,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
184,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
185,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
186,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
187,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
188,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
189,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
190,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
191,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
192,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
193,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
194,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
195,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
196,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
197,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Camrelizumab + Lenvatinib,,Recruiting,NCT04443309,,ECD,2022Aug01,No,No,,4,NCT04443309,Untreated,,Overall Response Rate,53.0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Aug04,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
198,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
199,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
200,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
201,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
202,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
203,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
204,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
205,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
206,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
207,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
208,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
209,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
210,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
211,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
212,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
213,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
214,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
215,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
216,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
217,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
218,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
219,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + TACE + Tremelimumab,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
220,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
221,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
222,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
223,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
224,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
225,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
226,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
227,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
228,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
229,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
230,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
231,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
232,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
233,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
234,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
235,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
236,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
237,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
238,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
239,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
240,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
241,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Durvalumab + Tremelimumab + Yttrium-90 SIRT,,Recruiting,NCT04522544,,ECD,2024Mar31,No,No,,4,NCT04522544,,,Overall Response Rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul22,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
242,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
243,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
244,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
245,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
246,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
247,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
248,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
249,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
250,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
251,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
252,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
253,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
254,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
255,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
256,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
257,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
258,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
259,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
260,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
261,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
262,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
263,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + MK-7684A,,Recruiting,NCT05007106,KEYVIBE-005,ECD,2025Feb19,Expression confirmed,No,,4,NCT05007106,,,"OS, PFS",610.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
264,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
265,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
266,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
267,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
268,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
269,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
270,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
271,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
272,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
273,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
274,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
275,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
276,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
277,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
278,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
279,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
280,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
281,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
282,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
283,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
284,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
285,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Thermal ablation + Toripalimab,,Recruiting,NCT05240404,,ECD,2023Jul31,No,No,,4,NCT05240404,Previously-treated,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",116.0,,,Thermal ablation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun15,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
286,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
287,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
288,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
289,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
290,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
291,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
292,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
293,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
294,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
295,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
296,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
297,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
298,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
299,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
300,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
301,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
302,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
303,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
304,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
305,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
306,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
307,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Nivolumab,,"Active, not recruiting",NCT03841201,IMMUNIB,ECD,2022Nov01,No,Yes,"SAE 30.6%, Primary outcome not met",2,10.1200/JCO.2022.40.16_suppl.4107,,,Overall Response Rate,50.0,50.0,,,28.0,,,,,,,,9.0,,,,,11.5,,,,,,,,27.1,,,,,,3.0,11.0,23.0,,,,,,,,,COSO29825606,2022Dec08,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
308,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
309,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
310,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
311,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
312,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
313,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
314,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
315,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
316,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
317,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
318,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
319,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
320,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
321,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
322,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
323,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
324,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
325,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
326,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
327,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
328,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
329,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lenvatinib + Tislelizumab,,Not yet recruiting,NCT04834986,,ECD,2022Apr30,No,No,,4,NCT04834986,,,Maximum tolerated dose/toxicity,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun07,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
330,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
331,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
332,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
333,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
334,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
335,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
336,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
337,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
338,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
339,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
340,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
341,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
342,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
343,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
344,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
345,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
346,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
347,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
348,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
349,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
350,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
351,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,743.0,371.0,372.0,Sorafenib,15.4,7.0,,,,,,,3.68,3.75,0.93,0.79-1.10,,,,,,,,,,16.39,14.69,0.85,0.71-1.02,0.0752,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
352,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
353,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
354,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
355,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
356,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
357,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
358,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
359,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
360,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
361,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
362,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
363,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
364,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
365,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
366,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
367,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
368,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
369,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
370,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
371,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
372,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
373,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Lenvatinib + Toripalimab,,Recruiting,NCT04523493,,ECD,2024May01,No,No,,4,NCT04523493,,,"OS, PFS",519.0,,,Lenvatinib + Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
374,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
375,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
376,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
377,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
378,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
379,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
380,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
381,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
382,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
383,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
384,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
385,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
386,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
387,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
388,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
389,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
390,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
391,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
392,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
393,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
394,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
395,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Icaritin,,Recruiting,NCT03236649,,ECD,2022Dec01,Expression confirmed,No,,4,NCT03236649,Untreated,,Overall survival,200.0,,,Sorafenib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jun20,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
396,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
397,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
398,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
399,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
400,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
401,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
402,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
403,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
404,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
405,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
406,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
407,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
408,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
409,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
410,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
411,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
412,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
413,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
414,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
415,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
416,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
417,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Atezolizumab + Bevacizumab,,"Active, not recruiting",NCT04102098,,ECD,2023Sep28,No,No,,4,NCT04102098,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",668.0,,,Observation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Jul28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
418,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
419,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
420,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
421,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
422,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
423,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
424,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
425,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
426,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
427,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
428,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
429,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
430,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
431,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
432,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
433,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
434,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
435,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
436,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
437,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
438,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
439,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS < 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,595.0,295.0,300.0,Sorafenib,12.2,6.7,,,,,,,3.61,3.75,0.98,0.81-1.17,,,,,,,,,,16.72,15.24,0.84,0.69-1.02,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
440,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
441,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
442,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
443,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
444,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
445,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
446,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
447,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
448,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
449,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
450,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
451,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
452,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
453,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
454,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
455,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
456,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
457,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
458,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
459,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
460,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
461,CD274,CD274_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 3,Nivolumab,,"Active, not recruiting",NCT02576509,PD-L1 PFS >= 1%,ECD,2019May30,No,Yes,,4,NCT02576509,,,Overall survival,135.0,71.0,64.0,Sorafenib,28.2,9.4,,,,,,,3.84,3.58,0.71,0.48-1.03,,,,,,,,,,16.07,8.62,0.8,0.54-1.19,,,,,,,,,,,,,,COSO29825606,2022Aug12,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
462,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
463,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
464,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
465,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
466,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
467,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
468,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
469,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
470,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
471,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
472,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
473,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
474,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
475,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
476,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
477,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
478,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
479,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
480,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
481,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
482,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
483,EGFR,EGFR_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,Yes,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
484,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
485,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
486,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
487,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
488,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
489,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
490,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
491,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
492,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
493,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
494,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
495,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
496,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
497,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
498,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
499,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
500,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
501,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
502,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
503,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
504,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
505,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Lapatinib,,Completed,NCT00107536,,PCD,2009May01,No,Yes,,1,19737952,,,Overall Response Rate,26.0,26.0,,,0,,,,,,,,1.9,,,,,,,,,,,,,12.6,,,,,,0.0,0.0,10.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
506,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
507,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
508,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
509,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
510,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
511,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
512,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
513,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
514,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
515,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
516,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
517,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
518,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
519,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
520,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
521,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
522,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
523,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
524,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
525,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
526,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
527,ERBB2,ERBB2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
528,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
529,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
530,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
531,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
532,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
533,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
534,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
535,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
536,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
537,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
538,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
539,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
540,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
541,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
542,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
543,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
544,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
545,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
546,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
547,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
548,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
549,ERBB3,ERBB3_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
550,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
551,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
552,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
553,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
554,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
555,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
556,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
557,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
558,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
559,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
560,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
561,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
562,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
563,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
564,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
565,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
566,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
567,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
568,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
569,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
570,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
571,ERBB4,ERBB4_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Varlitinib,,Unknown,NCT03499626,,ECD,2019May05,No,No,,4,NCT03499626,,,Maximum tolerated dose/toxicity,22.0,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
572,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
573,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
574,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
575,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
576,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
577,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
578,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
579,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
580,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
581,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
582,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
583,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
584,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
585,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
586,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
587,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
588,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
589,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
590,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
591,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
592,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
593,FGFR4,FGFR4_unspecified and KLB_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,FGF401 + Spartalizumab,,Completed,NCT02325739,,PCD,2019May30,Expression confirmed,Yes,,2,10.1158/1538-7445.AM2017-CT106,,,Overall Response Rate,53.0,53.0,,,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
594,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
595,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
596,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
597,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
598,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
599,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
600,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
601,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
602,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
603,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
604,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
605,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
606,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
607,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
608,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
609,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
610,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
611,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
612,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
613,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
614,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
615,JAK2,JAK2_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,AZD1480,,Terminated,NCT01219543,,PCD,2012Dec01,No,Yes,"Serious adverse events, no benefit of treatment",1,23847256,,,Unknown,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
616,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
617,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
618,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
619,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
620,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
621,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
622,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
623,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
624,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
625,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
626,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
627,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
628,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
629,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
630,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
631,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
632,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
633,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
634,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
635,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
636,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
637,KIT,KIT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Sunitinib,,Completed,NCT00247676,,PCD,2008Feb01,No,Yes,Serious adverse events - 4 deaths possibly due to treatment,1,19586800,,,Unknown,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
638,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
639,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
640,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
641,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
642,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
643,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
644,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
645,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
646,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
647,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
648,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
649,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
650,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
651,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
652,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
653,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
654,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
655,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
656,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
657,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
658,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
659,KRAS,KRAS_G12D,55497369 + 55865099,,p.G12D,liver / carcinoma / hepatocellular carcinoma,4,Case study,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
660,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
661,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
662,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
663,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
664,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
665,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
666,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
667,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
668,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
669,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
670,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
671,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
672,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
673,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
674,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
675,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
676,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
677,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
678,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
679,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
680,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
681,KRAS,KRAS_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,Refametinib + Sorafenib,,Completed,NCT01915602,,PCD,2015Jul29,Yes,Yes,,1,29950351,,,Overall Response Rate,16.0,16.0,,,6.3,,0.16-30.23,,,,,,,,,,,,,,,,43.8,,,,,,,,,0.0,1.0,4.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
682,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
683,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
684,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
685,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
686,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
687,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
688,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
689,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
690,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
691,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
692,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
693,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
694,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
695,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
696,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
697,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
698,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
699,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
700,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
701,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
702,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
703,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,Tepotinib,,Completed,NCT01988493,,PCD,2018Feb05,Expression confirmed,Yes,,4,NCT01988493,,,Time to progression,75.0,38.0,37.0,Sorafenib,,,,,,,,,2.8,1.4,0.53,0.33-0.84,0.0229,2.9,1.4,0.42,0.26-0.74,0.0043,,,,9.3,8.6,0.73,0.43-1.21,0.304,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
704,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
705,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
706,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
707,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
708,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
709,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
710,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
711,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
712,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
713,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
714,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
715,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
716,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
717,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
718,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
719,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
720,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
721,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
722,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
723,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
724,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
725,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 1,c-Met/PD-L1 CAR-T cells,,Unknown,NCT03672305,,ECD,2019Oct30,Expression confirmed,No,,4,NCT03672305,,,Clinical activity,50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022May03,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
726,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
727,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
728,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
729,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
730,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
731,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
732,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
733,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
734,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
735,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
736,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
737,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
738,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
739,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
740,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
741,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
742,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
743,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
744,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
745,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
746,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
747,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,Withdrawn,NCT01964235,,ECD,2019Jul01,Expression confirmed,No,,4,NCT01964235,,,Time to progression,0.0,0.0,0.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Jun14,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
748,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
749,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
750,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
751,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
752,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
753,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
754,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
755,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
756,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
757,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
758,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
759,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
760,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
761,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
762,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
763,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
764,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
765,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
766,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
767,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
768,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
769,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,RC108,,Not yet recruiting,NCT05628857,,ECD,2024Oct15,Expression confirmed,No,,4,NCT05628857,,,Overall Response Rate,240.0,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2023Jan10,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
770,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
771,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
772,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
773,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
774,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
775,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
776,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
777,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
778,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
779,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
780,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
781,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
782,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
783,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
784,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
785,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
786,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
787,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
788,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
789,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
790,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
791,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Cabozantinib + Nivolumab,,Not yet recruiting,NCT05039736,,ECD,2023Jun30,No,No,,4,NCT05039736,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021Nov19,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
792,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
793,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
794,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
795,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
796,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
797,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
798,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
799,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
800,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
801,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
802,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
803,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
804,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
805,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
806,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
807,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
808,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
809,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
810,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
811,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
812,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
813,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Tepotinib,,Completed,NCT02115373,,PCD,2018Feb14,Expression confirmed,Yes,"PFS 12w 63.3%, Primary outcome met",4,NCT02115373,Previously-treated,,Progression free survival,49.0,49.0,,,,8.2,,,,,,,,,,,,,,,,,57.1,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
814,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
815,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
816,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
817,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
818,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
819,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
820,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
821,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
822,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
823,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
824,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
825,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
826,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
827,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
828,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
829,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
830,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
831,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
832,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
833,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
834,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
835,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 2,Capmatinib,,"Active, not recruiting",NCT01737827,,ECD,2023May31,Expression confirmed,Yes,,2,10.1200/JCO.2016.34.15_suppl.4074,Untreated,,Time to progression,8.0,8.0,,,38,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,3.0,1.0,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
836,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
837,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
838,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
839,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
840,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
841,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
842,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
843,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
844,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
845,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
846,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
847,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
848,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
849,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
850,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
851,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
852,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
853,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
854,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
855,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
856,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
857,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT01755767,METIV-HCC,PCD,2017Mar28,Expression confirmed,Yes,Primary outcome not met,1,29625879,,,Overall survival,340.0,226.0,114.0,Placebo,,,,,,,,,,,,,,,,,,,,,,8.4,9.1,0.97,0.75-1.25,0.81,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
858,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
859,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
860,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
861,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
862,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
863,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
864,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
865,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
866,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
867,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
868,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
869,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
870,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
871,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
872,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
873,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
874,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
875,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
876,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
877,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
878,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
879,MET,MET_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,2,Phase 3,Tivantinib,,Completed,NCT02029157,,PCD,2017Aug01,Expression confirmed,Yes,,1,32716114,,,Progression free survival,195.0,134.0,61.0,,0.7,1.6,,,,,,,2.8,2.3,0.74,0.52?1.04,0.082,,,,,,67.2,55.7,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov28,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
880,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
881,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
882,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
883,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
884,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
885,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
886,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
887,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
888,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
889,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
890,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
891,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
892,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
893,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
894,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
895,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
896,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
897,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
898,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
899,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
900,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
901,NOTCH1,NOTCH1_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Unknown,Ginsenoside Rg3 capsule + Pirarubicin,,Completed,NCT02724358,,PCD,2013Dec01,Expression confirmed,No,,4,NCT02724358,,,"TTP, OS",320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov23,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
902,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
903,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
904,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
905,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
906,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
907,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
908,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
909,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
910,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
911,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
912,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
913,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
914,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
915,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
916,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
917,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
918,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
919,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
920,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
921,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
922,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
923,TERT,TERT_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,RZ001,,Recruiting,NCT05595473,,ECD,2029Mar01,Yes,No,,4,NCT05595473,,,"ORR, PFS, OS",42.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2022Nov21,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
924,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
925,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
926,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
927,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
928,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
929,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
930,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
931,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
932,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
933,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
934,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
935,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
936,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
937,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
938,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
939,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
940,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
941,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
942,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
943,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
944,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
945,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 1,Ad5CMV-p53 gene,,Terminated,NCT00003147,,PCD,2003Jun01,No,No,,4,NCT00003147,,,Unknown,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
946,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
947,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
948,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
949,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
950,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
951,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
952,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
953,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
954,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
955,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
956,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
957,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
958,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
959,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
960,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
961,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
962,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
963,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
964,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
965,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
966,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
967,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02509169,,ECD,2016Dec01,No,Yes,,4,NCT02509169,,,Overall survival,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,15.0,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
968,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
969,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
970,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
971,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
972,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
973,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
974,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
975,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
976,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
977,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
978,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
979,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
980,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
981,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
982,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
983,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
984,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
985,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
986,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
987,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
988,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
989,TP53,TP53_unspecified,,,,liver / carcinoma / hepatocellular carcinoma,3,Phase 2,rAD-p53,,Unknown,NCT02418988,,ECD,2017May01,No,No,,4,NCT02418988,,,Overall survival,120.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29825606,2021May18,COSO29825606,liver,NS,NS,NS,carcinoma,hepatocellular_carcinoma,NS,NS
